Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312385 | 0.90 | MAPK1 (0.62) | SLC6A7TP53MAPTTSHRMAPK1 | |
| SCHEMBL4417155 | 0.90 | SLC6A7 (0.65) | SLC6A7NAMPT | |
| SCHEMBL4314125 | 0.86 | KDM4E (0.52) | GRM5 | |
| SCHEMBL4319854 | 0.86 | SLC6A7 (0.62) | SLC6A7NAMPTTP53MAPTTSHR | |
| SCHEMBL4318289 | 0.85 | KDM4E (0.57) | SLC6A7TSHR | |
| SCHEMBL4326371 | 0.83 | SMN1; SMN2 (0.50) | NAMPTMAPTTSHRMAPK1GRM5 | |
| SCHEMBL4415931 | 0.83 | SLC6A7 (0.61) | SLC6A7NAMPT | |
| SCHEMBL11080932 | 0.82 | SLC6A7 (0.85) | SLC6A7NAMPTMAPK1 | |
| SCHEMBL4319285 | 0.82 | TIPARP (0.48) | TP53MAPTTSHRMAPK1NPSR1 | |
| SCHEMBL4425017 | 0.81 | SLC6A7 (0.56) | SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | SLC6A7 234/4885NAMPT 3332/4885TP53 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.